End-Stage Renal Disease

End-Stage Renal Disease

Global End-Stage Renal Disease Market to Reach US$286.5 Billion by 2030

The global market for End-Stage Renal Disease estimated at US$133.1 Billion in the year 2023, is expected to reach US$286.5 Billion by 2030, growing at a CAGR of 11.6% over the analysis period 2023-2030. Hemodialysis Treatment, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$209.9 Billion by the end of the analysis period. Growth in the Peritoneal Dialysis Treatment segment is estimated at 9.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$34.5 Billion While China is Forecast to Grow at 15.4% CAGR

The End-Stage Renal Disease market in the U.S. is estimated at US$34.5 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$69.2 Billion by the year 2030 trailing a CAGR of 15.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.7% and 9.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.

End-Stage Renal Disease (ESRD) - Key Insights and Treatment Trends

What Is End-Stage Renal Disease and Why Is It a Critical Health Concern?

End-Stage Renal Disease (ESRD), also known as end-stage kidney disease, is the final stage of chronic kidney disease (CKD), where kidney function declines to a point where the kidneys can no longer adequately filter waste and fluids from the blood. ESRD occurs when kidney function drops below 10-15% of normal levels, resulting in an accumulation of waste products and fluids that can be life-threatening without intervention. Patients with ESRD require long-term dialysis or a kidney transplant to sustain life. The primary causes of ESRD include diabetes, hypertension, and glomerulonephritis, which progressively damage kidney function over time. With the global rise in diabetes and hypertension, ESRD has become a critical public health issue, leading to high healthcare costs, patient morbidity, and mortality.

ESRD places a substantial burden on healthcare systems due to its chronic nature and the high cost of treatment, particularly dialysis and transplantation. Patients often experience complications such as cardiovascular disease, anemia, and bone disorders, necessitating comprehensive care that includes medication management, lifestyle changes, and frequent medical visits. As the prevalence of ESRD rises, addressing the condition with innovative therapies and early intervention has become a priority for improving patient quality of life and alleviating healthcare system demands.

What Are the Main Treatment Options for ESRD?

The two primary treatment options for ESRD are dialysis and kidney transplantation. Dialysis, which includes hemodialysis and peritoneal dialysis, helps remove waste products and excess fluids from the blood, effectively acting as an artificial kidney. Hemodialysis is typically performed in a dialysis center or at home and requires a machine to filter the blood, while peritoneal dialysis involves inserting a catheter into the abdomen and using the peritoneal lining as a filter. Both methods have advantages and limitations, with hemodialysis often providing more intensive care but requiring regular visits to a dialysis center, and peritoneal dialysis allowing more independence for patients.

Kidney transplantation, considered the most effective treatment, provides ESRD patients with a functioning kidney that can support normal body functions without the need for dialysis. However, kidney transplants require a compatible donor, and waiting lists are often long due to a shortage of available organs. Additionally, patients must take lifelong immunosuppressive medications to prevent organ rejection, which carries risks of infection and other complications. Both treatment options are essential in managing ESRD, with dialysis being the primary treatment for many due to organ shortages and accessibility challenges.

How Are Technological and Therapeutic Advancements Shaping ESRD Management?

Technological advancements and innovative therapies are improving the quality of life for ESRD patients and making treatment more accessible. New developments in dialysis, such as wearable and portable hemodialysis machines, are making it easier for patients to undergo treatment while maintaining mobility and independence. Portable dialysis systems reduce the need for frequent clinic visits, supporting patients in managing their condition at home or even while traveling, enhancing their quality of life. Advances in peritoneal dialysis technology, including automated systems and improved fluid management, are also reducing the burden of dialysis on patients and caregivers.

In kidney transplantation, advancements in immunosuppressive therapies and donor organ matching are improving success rates and reducing the risk of rejection. Research into bioengineered organs and xenotransplantation (transplanting animal organs into humans) is also showing potential as a future solution to the organ shortage crisis. Additionally, innovative therapeutic approaches, such as regenerative medicine and stem cell research, are exploring ways to repair damaged kidney tissue, which could eventually delay or prevent the need for dialysis or transplant in patients with CKD. These advancements are creating a more patient-centered approach to ESRD care, providing hope for improved treatment options and longer, healthier lives for patients.

What Is Driving Growth in ESRD Cases and How Can It Be Addressed?

The global increase in ESRD cases is primarily driven by the rise in diabetes and hypertension, both of which are major risk factors for kidney disease. Aging populations, lifestyle changes, and increased prevalence of obesity are also contributing to the growth in ESRD cases worldwide. Preventing the progression of chronic kidney disease to ESRD requires early detection and effective management of underlying conditions. Many healthcare systems are implementing screening programs to identify kidney disease in high-risk populations, such as those with diabetes or high blood pressure, allowing for earlier interventions that can slow disease progression.

Addressing ESRD on a larger scale requires a focus on public health initiatives to promote healthy lifestyles, improve access to healthcare, and reduce the incidence of conditions that lead to kidney disease. Education campaigns emphasizing healthy eating, physical activity, and regular check-ups are essential for reducing the impact of ESRD. Additionally, policies to improve access to early-stage treatment, support research into new therapies, and increase organ donation rates are vital for managing the growing demand for ESRD care. Together, these efforts—early detection, technological advancements, lifestyle education, and policy support—are essential for addressing the global ESRD burden and improving outcomes for affected individuals.

Select Competitors (Total 33 Featured) -
  • Asahi Kasei Medical Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • BD
  • Cantel Medical
  • Fresenius Medical Care Ag & Co. KGAA
  • Jms Co. Ltd
  • Medtronic
  • Nikkiso Co., Ltd.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
End-Stage Renal Disease – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Diabetes and Hypertension as Leading Causes of ESRD Drives Demand for Advanced Treatment Solutions
Increasing Incidence of Chronic Kidney Disease (CKD) Progression to ESRD Spurs Demand for Dialysis and Transplantation Services
Technological Innovations in Dialysis Machines Improve Treatment Efficiency and Patient Comfort, Expanding Market Potential
Growing Demand for Home-Based Dialysis Options Expands Accessibility and Convenience for ESRD Patients
Expansion of Kidney Transplant Programs in Developed Markets Increases Demand for Organ Donor Matching and Allocation Systems
Rising Healthcare Expenditure on ESRD Management Drives Development of High-Quality, Cost-Effective Dialysis and Support Services
Advances in Hemodialysis Membranes and Dialyzers Improve Treatment Efficacy, Reducing Complications in ESRD Management
Increasing Use of Wearable Dialysis Devices Expands Patient Mobility and Quality of Life for ESRD Sufferers
Growing Adoption of Peritoneal Dialysis as an Alternative to Hemodialysis Expands Treatment Options for ESRD Patients
Increasing Focus on Early Detection and Slowing CKD Progression Helps to Delay Onset of ESRD, Impacting Long-Term Market Demand
Rise in Geriatric Population with High Susceptibility to ESRD Drives Demand for Long-Term Dialysis and Supportive Care
Development of Artificial Kidneys and Bioengineered Organs Promises New Avenues for ESRD Treatment and Market Growth
Expanding Use of Telemedicine in ESRD Management Improves Patient Monitoring and Compliance with Treatment Regimens
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for End-Stage Renal Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for End-Stage Renal Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for End-Stage Renal Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Hemodialysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Hemodialysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Hemodialysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Peritoneal Dialysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Peritoneal Dialysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Peritoneal Dialysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World End-Stage Renal Disease Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
End-Stage Renal Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 14: USA Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 15: USA Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: USA 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
CANADA
TABLE 17: Canada Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 18: Canada Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: Canada 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
JAPAN
End-Stage Renal Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 20: Japan Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: Japan Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: Japan 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
CHINA
End-Stage Renal Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 23: China Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: China Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: China 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
EUROPE
End-Stage Renal Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 26: Europe Recent Past, Current & Future Analysis for End-Stage Renal Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: Europe Historic Review for End-Stage Renal Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: Europe 16-Year Perspective for End-Stage Renal Disease by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 29: Europe Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: Europe Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Europe 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
FRANCE
End-Stage Renal Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 32: France Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: France Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: France 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
GERMANY
End-Stage Renal Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 35: Germany Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Germany Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Germany 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
ITALY
TABLE 38: Italy Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Italy Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Italy 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
UNITED KINGDOM
End-Stage Renal Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 41: UK Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: UK Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: UK 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
SPAIN
TABLE 44: Spain Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Spain Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Spain 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
RUSSIA
TABLE 47: Russia Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Russia Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Russia 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Rest of Europe Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Rest of Europe 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
ASIA-PACIFIC
End-Stage Renal Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for End-Stage Renal Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 54: Asia-Pacific Historic Review for End-Stage Renal Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Asia-Pacific 16-Year Perspective for End-Stage Renal Disease by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Asia-Pacific Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Asia-Pacific 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
AUSTRALIA
End-Stage Renal Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 59: Australia Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Australia Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Australia 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
INDIA
End-Stage Renal Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 62: India Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: India Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: India 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 65: South Korea Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: South Korea Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: South Korea 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Rest of Asia-Pacific Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Rest of Asia-Pacific 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
LATIN AMERICA
End-Stage Renal Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 71: Latin America Recent Past, Current & Future Analysis for End-Stage Renal Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 72: Latin America Historic Review for End-Stage Renal Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Latin America 16-Year Perspective for End-Stage Renal Disease by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 74: Latin America Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Latin America Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Latin America 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 77: Argentina Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Argentina Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Argentina 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
BRAZIL
TABLE 80: Brazil Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Brazil Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Brazil 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
MEXICO
TABLE 83: Mexico Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Mexico Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Mexico 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Rest of Latin America Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Rest of Latin America 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
MIDDLE EAST
End-Stage Renal Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 89: Middle East Recent Past, Current & Future Analysis for End-Stage Renal Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 90: Middle East Historic Review for End-Stage Renal Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Middle East 16-Year Perspective for End-Stage Renal Disease by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 92: Middle East Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Middle East Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Middle East 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
IRAN
TABLE 95: Iran Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Iran Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Iran 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
ISRAEL
TABLE 98: Israel Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Israel Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Israel 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Saudi Arabia Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Saudi Arabia 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 104: UAE Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: UAE Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: UAE 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Rest of Middle East Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Rest of Middle East 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
AFRICA
End-Stage Renal Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 110: Africa Recent Past, Current & Future Analysis for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Africa Historic Review for End-Stage Renal Disease by Treatment Type - Hemodialysis, Peritoneal Dialysis and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Africa 16-Year Perspective for End-Stage Renal Disease by Treatment Type - Percentage Breakdown of Value Sales for Hemodialysis, Peritoneal Dialysis and Other Treatment Types for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings